Brain, Vol. 125, No. 7, 1462-1473,
July 2002
© 2002 Guarantors of Brain
Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations
1 Department of Neuroinflammation, Institute of Neurology, Queen Square, London, UK and 2 Department of Neurology, VU Medical Center, Amsterdam, The Netherlands
Correspondence to: A. Petzold, Department of Neuroinflammation, Institute of Neurology, Queen Square, London WC1N 3BG, UK E-mail: a.petzold{at}ion.ucl.ac.uk
Disease progression in multiple sclerosis occurs within the interface of glial activation and gliosis. This study aimed to investigate the relationship between biomarkers of different glial cell responses: (i) to disease dynamics and the clinical subtypes of multiple sclerosis; (ii) to disability; and (iii) to cross-validate these findings in a post-mortem study. To address the first goal, 51 patients with multiple sclerosis [20 relapsing remitting (RR), 21 secondary progressive (SP) and 10 primary progressive (PP)] and 51 neurological control patients were included. Disability was assessed using the ambulation index (AI), the Expanded Disability Status Scale score (EDSS) and the 9-hole PEG test (9HPT). Patients underwent lumbar puncture within 7 days of clinical assessment. Post-mortem brain tissue (12 multiple sclerosis and eight control patients) was classified histologically and adjacent sites were homogenized for protein analysis. S100B, ferritin and glial-fibrillary acidic protein (GFAP) were quantified in CSF and brain-tissue homogenate by ELISA (enzyme-linked immunosorbent assay) techniques developed in-house. There was a significant trend for increasing S100B levels from PP to SP to RR multiple sclerosis (P < 0.05). S100B was significantly higher in RR multiple sclerosis than in control patients (P < 0.01), whilst ferritin levels were significantly higher in SP multiple sclerosis than in control patients (P < 0.01). The S100B : ferritin ratio discriminated patients with RR multiple sclerosis from SP, PP or control patients (P < 0.05, P < 0.01 and P < 0.01, respectively). Multiple sclerosis patients with poor ambulation (AI 
7) or severe disability (EDSS >6.5) had significantly higher CSF GFAP levels than less disabled multiple sclerosis or control patients (P < 0.01 and P < 0.001, respectively). There was a correlation between GFAP levels and ambulation in SP multiple sclerosis (r = 0.57, P < 0.01), and between S100B level and the 9HPT in PP multiple sclerosis patients (r = –0.85, P < 0.01). The post-mortem study showed significantly higher S100B levels in the acute than in the subacute plaques (P < 0.01), whilst ferritin levels were elevated in all multiple sclerosis lesion stages. Both GFAP and S100B levels were significantly higher in the cortex of multiple sclerosis than in control brain homogenate (P < 0.001 and P < 0.05, respectively). We found that S100B is a good marker for the relapsing phase of the disease (confirmed by post-mortem observation) as opposed to ferritin, which is elevated throughout the entire course. GFAP correlated with disability scales and may therefore be a marker for irreversible damage. The results of this study have broad implications for finding new and sensitive outcome measures for treatment trials that aim to delay the development of disability. They may also be considered in future classifications of multiple sclerosis patients.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T Misu, R Takano, K Fujihara, T Takahashi, S Sato, and Y Itoyama Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker J. Neurol. Neurosurg. Psychiatry, May 1, 2009; 80(5): 575 - 577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rejdak, A. Petzold, Z. Stelmasiak, and G. Giovannoni Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis Multiple Sclerosis, January 1, 2008; 14(1): 59 - 66. [Abstract] [PDF]
|
|
|
|
|
|
K.M. Mitchell, A.L. Dotson, K.M. Cool, A. Chakrabarty, S.H. Benedict, and S.M. LeVine Deferiprone, an orally deliverable iron chelator, ameliorates experimental autoimmune encephalomyelitis Multiple Sclerosis, November 1, 2007; 13(9): 1118 - 1126. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Ohtaki, W. Kamitani, Y. Watanabe, Y. Hayashi, H. Yanai, K. Ikuta, and K. Tomonaga Downregulation of an Astrocyte-Derived Inflammatory Protein, S100B, Reduces Vascular Inflammatory Responses in Brains Persistently Infected with Borna Disease Virus J. Virol., June 1, 2007; 81(11): 5940 - 5948. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J N. Zwemmer, J Berkhof, J A Castelijns, F Barkhof, C H Polman, and B M. Uitdehaag Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics Multiple Sclerosis, September 1, 2006; 12(5): 565 - 572. [Abstract] [PDF]
|
|
|
|
|
|
A Petzold, M J Eikelenboom, G Keir, C H Polman, B M. Uitdehaag, E J Thompson, and G Giovannoni The new Global Multiple Sclerosis Severity Score (MSSS) correlates with axonal but not glial biomarkers Multiple Sclerosis, June 1, 2006; 12(3): 325 - 328. [Abstract] [PDF]
|
|
|
|
 |
|
 J.-H. F. Peng, F.-T. Kung, W. Peng, and J. C. Parker Jr Increased ALZ-50 Immunoreactivity in CSF of Pseudotumor Cerebri Patients. Ann. Clin. Lab. Sci., March 1, 2006; 36(2): 151 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rostasy, E. Withut, D. Pohl, P. Lange, B. Ciesielcyk, R. Diem, J. Gartner, and M. Otto Tau, Phospho-Tau, and S-100B in the Cerebrospinal Fluid of Children With Multiple Sclerosis J Child Neurol, October 1, 2005; 20(10): 822 - 825. [Abstract] [PDF]
|
|
|
|
 |
|
 R. A. Bermel, S. R. Puli, R. A. Rudick, B. Weinstock-Guttman, E. Fisher, F. E. Munschauer III, and R. Bakshi Prediction of Longitudinal Brain Atrophy in Multiple Sclerosis by Gray Matter Magnetic Resonance Imaging T2 Hypointensity Arch Neurol, September 1, 2005; 62(9): 1371 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Petzold, H Perron, K T. Fernando, and G. T Plant No evidence for MSRV viraemia and glial cell death in acute optic neuritis Multiple Sclerosis, August 1, 2005; 11(4): 495 - 496. [PDF]
|
|
|
|
|
|
A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, and G Giovannoni Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 206 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Norgren, P. Sundstrom, A. Svenningsson, L. Rosengren, T. Stigbrand, and M. Gunnarsson Neurofilament and glial fibrillary acidic protein in multiple sclerosis Neurology, November 9, 2004; 63(9): 1586 - 1590. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rejdak, M. J. Eikelenboom, A. Petzold, E. J. Thompson, Z. Stelmasiak, R. H.C. Lazeron, F. Barkhof, C. H. Polman, B. M.J. Uitdehaag, and G. Giovannoni CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis Neurology, October 26, 2004; 63(8): 1439 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E T Lim, D Grant, M Pashenkov, G Keir, E J Thompson, M Soderstrom, and G Giovannoni Cerebrospinal fluid levels of brain specific proteins in optic neuritis Multiple Sclerosis, June 1, 2004; 10(3): 261 - 265. [Abstract] [PDF]
|
|
|
|
|
|
A Petzold, D Brassat, P Mas, K Rejdak, G Keir, G Giovannoni, E J Thompson, and M. Clanet Treatment response in relation to inflammatory and axonal surrogate marker in multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(3): 281 - 283. [Abstract] [PDF]
|
|
|
|
|
|
C. Malmestrom, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS Neurology, December 23, 2003; 61(12): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|